By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Purdue Pharma Products LP et. al. v. Par Pharmaceuticals Inc. et. al.
1:07-cv-00255; filed May 9, 2007 in the District Court of Delaware
Infringement of U.S. Patent No. 6,254,887 ("Controlled Release Tramadol," issued July 3, 2001) following a paragraph IV certification as part of Par's filing of an ANDA to manufacture a generic version of plaintiffs' Ultram® ER (tramadol hydrochloride, used to treat moderate to moderately severe chronic pain). View the complaint here.
Abbott Laboratories v. Teva Pharmaceuticals USA Inc.
1:07-cv-00250; filed May 4, 2007 in the District Court of Delaware
Infringement of U.S. Patent No. 6,419,953 ("Controlled Release Formulation of Divalproex Sodium," issued July 16, 2002) following a paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Abbott's Depakote® ER (divalproex sodium, used to treat manic episodes associated with bipolar disorder). View the complaint here.
Bioglan Pharmaceuticals Corp. et. al. v. Novartis Consumer Health, Inc.
2:07-cv-02075; filed May 3, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 5,852,002 ("Treatment of Conditions and Disease," issued December 22, 1998), 5,929,048 (same title, issued July 27, 1999), and 5,985,850 ("Compositions Comprising Hyaluronic Acid and Drugs," issued November 16, 1999) following a paragraph IV certification as part of Novartis' filing of an NDA (under § 505(b)(2) of the Food, Drug and Cosmetic Act) to manufacture a generic version of Bioglan's Solaraze® (diclofenac sodium, used to actinic keratosis). View the complaint here.
Comments